Business
Klarna valuation
Sherwood News

Buy now, pay later giant Klarna is finally ready to file for IPO

BNPL players nearly collapsed postpandemic, but they are back, stronger and focused.

Buy now, pay later company Klarna is only days away from filing its long-awaited initial public offering. With aims to price the IPO in early April, the Stockholm-based fintech is targeting a valuation of more than $15 billion, per Bloomberg.

For what was once one of the world’s most valuable startups, hitting a $45.6 billion valuation at its peak, Klarna’s $15 billion target may seem modest. But after the market pulled back in 2022 and interest rates started rising, investors became increasingly cautious about tech startups that were losing money — unless they had some sort of AI angle, of course. Since then, the Swedish BNPL giant’s been slowly recovering, with its valuation rising to ~$14.6 billion last year.

Buy now, regret later

The rise and fall and rise again of Klarna’s valuation is essentially a microcosmic history of the entire BNPL space. By enabling users to split the cost of a purchase across interest-free installments, BNPL was hailed as a revolution, despite basically being, when all’s said and done, a rebranding of one of the most fundamental financial concepts: credit.

Faced with the pressure to stem its losses and become profitable, Klarna’s American rival Affirm has leaned more on interest-bearing lending, which made up 72% of its loans in 2024, a 33% year-over-year growth. Klarna itself even introduced a Klarna card, which it claims is different from a credit card, but the principals remain pretty similar — you can pay it off every month, or “choose to pay over 3 or 6 months with added interest.” Very credit card-y. The company’s also been busy striking new deals with key payment partners like Stripe and JPMorgan, while shedding businesses and staff to cut costs.

The initiatives for both Affirm and Klarna do seem to be making an impact on the bottom line: Affirm posted its first profit as a public company last month and Klarna almost broke even for the first time since 2019 in November.

Correction (March 7 2025): In an earlier version of this article, we incorrectly said that Affirm had stopped offering interest-free loans. This has been corrected.

More Business

See all Business
business

Ford reportedly in talks to buy hybrid vehicle batteries from Chinese auto giant BYD

Detroit’s Ford and China’s BYD are said to be in ongoing talks to partner on an agreement that would see Ford buy hybrid vehicle batteries from BYD, according to reporting from The Wall Street Journal.

The report comes just days after President Trump toured a Ford factory in Michigan and implied openness to Chinese automakers coming to the US.

“If they want to come in and build a plant... that’s great, I love that,” Trump said on January 13. “Let China come in, let Japan come in.”

Last week, China’s Geely Automobile Holdings said it expects to make an announcement about expanding into the US within the next three years. Chinese carmakers currently face huge tariffs and software restrictions, effectively barring their vehicles from the US.

Ford has doubled down on hybrid vehicles amid high EV costs and the end of federal EV tax credits. The automaker is currently building a battery plant in Michigan where it plans to use tech from Chinese battery maker CATL.

“If they want to come in and build a plant... that’s great, I love that,” Trump said on January 13. “Let China come in, let Japan come in.”

Last week, China’s Geely Automobile Holdings said it expects to make an announcement about expanding into the US within the next three years. Chinese carmakers currently face huge tariffs and software restrictions, effectively barring their vehicles from the US.

Ford has doubled down on hybrid vehicles amid high EV costs and the end of federal EV tax credits. The automaker is currently building a battery plant in Michigan where it plans to use tech from Chinese battery maker CATL.

Still life of Ozempic and Wegovy with weight scale.

Lawsuit alleges Lilly, Novo locked up telehealth to kill compounded GLP-1s

Novo Nordisk CEO Mike Doustdar estimated that around 1.5 million US patients are using compounded versions of the company’s drugs.

Handshake

Big Pharma enters 2026 with an appetite for deals

At the JPMorgan Healthcare Conference, biotechs and Big Pharma signaled they’re primed for M&A this year, after a big year for deals in 2025.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.